Global Kinetics Corporation09.30.16
Global Kinetics Corporation has received 510(k) clearance from the U.S. Food and Drug Administration to market its second-generation technology, the PKG (Personal KinetiGraph) Watch.
Clearance of this technology signals a major milestone for Global Kinetics, underpinning aggressive expansion into new product and service offers to meet the needs of the Parkinson’s community worldwide, according to the company.
The new technology is a core platform for the Australian company to reach scale in the U.S., European and Asia Pacific clinical care markets by overcoming previous distribution and data handling constraints. It enables GKC to capitalize on its growing telehealth and clinical trial services businesses, and to build on its partnerships with global pharmaceutical and device leaders.
Developed based on extensive feedback from users of the previous-generation PKG, the second-generation PKG is smaller, more compact and includes a touch sensitive backlit screen with haptic and visual feedback, a water resistance enclosure and mobile charging and data handling capacity.
The PKG-Watch was unveiled at the World Parkinson’s Congress 2016 in Portland, Ore., before being distributed to patients and physicians in key movement disorder clinics across the United States.
Global Kinetics Corporation (GKC) was established in 2007 to commercialize technology developed by Professor Malcolm Horne from the Florey Institute of Neuroscience & Mental Health (the largest Neuroscience research team in Australia and the Southern Hemisphere), and Dr. Rob Griffiths, for the precise recording, quantification and reporting of movement symptoms of neurological disease.
Clearance of this technology signals a major milestone for Global Kinetics, underpinning aggressive expansion into new product and service offers to meet the needs of the Parkinson’s community worldwide, according to the company.
The new technology is a core platform for the Australian company to reach scale in the U.S., European and Asia Pacific clinical care markets by overcoming previous distribution and data handling constraints. It enables GKC to capitalize on its growing telehealth and clinical trial services businesses, and to build on its partnerships with global pharmaceutical and device leaders.
Developed based on extensive feedback from users of the previous-generation PKG, the second-generation PKG is smaller, more compact and includes a touch sensitive backlit screen with haptic and visual feedback, a water resistance enclosure and mobile charging and data handling capacity.
The PKG-Watch was unveiled at the World Parkinson’s Congress 2016 in Portland, Ore., before being distributed to patients and physicians in key movement disorder clinics across the United States.
Global Kinetics Corporation (GKC) was established in 2007 to commercialize technology developed by Professor Malcolm Horne from the Florey Institute of Neuroscience & Mental Health (the largest Neuroscience research team in Australia and the Southern Hemisphere), and Dr. Rob Griffiths, for the precise recording, quantification and reporting of movement symptoms of neurological disease.